Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Karuna Therapeutics Inc (NQ: KRTX )

161.33 -21.17 (-11.60%)
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 21, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,497,398
Open 182.36
Bid (Size) 162.00 (2)
Ask (Size) 163.75 (4)
Prev. Close 182.50
Today's Range 159.73 - 182.36
52wk Range 92.26 - 278.25
Shares Outstanding 34,515,033
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Karuna Therapeutics Announces Pricing of Public Offering of Common Stock
From Karuna Therapeutics, Inc.
Via Business Wire
Why Citi Trends Shares Are Trading Lower By Over 14%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Gainers U.S. Xpress Enterprises, Inc. (NYSE: USX) shares surged 298% to $5.97 after Knight-Swift Transportation agreed to acquire the company for $6.15 per share. 
Via Benzinga

Performance

YTD
-16.49%
-16.49%
1 Month
-14.27%
-14.27%
3 Month
-17.27%
-17.27%
6 Month
-33.30%
-33.30%
1 Year
+38.99%
+38.99%

More News

Read More
Analyst Expectations for Karuna Therapeutics's Future
Via Benzinga
Karuna Surges To Three-Month High On Another Win In Schizophrenia
Via Investor's Business Daily
The Latest Analyst Ratings for Karuna Therapeutics
Via Benzinga
Looking Into Karuna Therapeutics's Return On Capital Employed
Via Benzinga
Karuna Therapeutics Announces Proposed Public Offering of Common Stock
From Karuna Therapeutics, Inc.
Via Business Wire
ENPH Stock Price Prediction: Can Enphase Energy Really Hit $225?
Via InvestorPlace
UBS Stock Price Prediction: Why This Analyst Says UBS Is a ‘Buy’
Via InvestorPlace
Karuna Therapeutics Says It One Step Closer To Potential Treatment Option After Encouraging Schizophrenia Data
Via Benzinga
Why Is Karuna Therapeutics (KRTX) Stock Moving Today?
Via InvestorPlace
Analyst Expectations for Karuna Therapeutics's Future
Via Benzinga
Zai Lab Partner Karuna Therapeutics Announces Positive Results from Phase 3 EMERGENT-3 Trial of KarXT in Schizophrenia
From Zai Lab Limited
Via Globe NewsWire
Karuna Therapeutics Announces Positive Results from Phase 3 EMERGENT-3 Trial of KarXT in Schizophrenia
From Karuna Therapeutics, Inc.
Via Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For March 8, 2023
Via Benzinga
Ciena, Apple And 3 Stocks To Watch Heading Into Monday
Via Benzinga
Target To Rally 20%? Here Are 10 Other Analyst Forecasts For Thursday
Via Benzinga
Karuna Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Result and Provides General Business Updates
From Karuna Therapeutics, Inc.
Via Business Wire
Karuna Therapeutics to Present at the SVB Securities Global Biopharma Conference
From Karuna
Via Business Wire
Analyst Views Karuna Therapeutics' New Licensing Deal 'As Intriguing'
Via Benzinga
Karuna Therapeutics Announces Exclusive Global License Agreement for Goldfinch Bio’s Investigational TRPC4/5 Product Candidates
From Karuna Therapeutics, Inc.
Via Business Wire
Karuna Therapeutics Appoints William P. Kane as Chief Commercial Officer
From Karuna Therapeutics, Inc.
Via Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For January 27, 2023
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For January 5, 2023
Via Benzinga
Karuna Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
From Karuna Therapeutics, Inc.
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.